DARPA Awards Techulon $1.9M to Develop ‘Superbug’ Drug
The Defense Advanced Research Projects Agency (DARPA) has awarded Techulon $1.9 million to advances its therapeutic program for multidrug-resistant bacteria, so-called superbugs, through a Phase II contract, the nucleic acid therapeutics development firm said.
Through this award, Techulon aims to advance the development of a nanotherapeutic agent through critical milestones toward clinical trials, the company added.
“We are pleased to extend our work in Rapidly Adaptable Therapeutics with DARPA. This program will lead to better therapies for wounded soldiers and civilians affected by multi-drug resistant hospital-acquired infections,” Techulon CSO Joshua Bryson, Ph.D., said in a statement.